Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults
NCT03912207Phase 1Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Apr 2019
- Primary completion
- Jun 2024
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bacillus calmette-guerin substrain danish 1331 live antigen in Tuberculosis (TB) (8 arms), sponsored by University of Oxford. Primary endpoints: Identification of markers of innate immunity-cytokines, Identification of markers of innate immunity-antigen presenting cells and 3 more. Started Apr 2019; status: active, not recruiting.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigen
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03912207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912207.